Published in J Clin Microbiol on August 26, 2009
The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev (2010) 4.48
Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis (2013) 3.56
Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis (2013) 3.15
Current status of Clostridium difficile infection epidemiology. Clin Infect Dis (2012) 3.14
Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J Clin Microbiol (2010) 2.47
Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol (2010) 2.32
Characterisation of Clostridium difficile hospital ward-based transmission using extensive epidemiological data and molecular typing. PLoS Med (2012) 2.12
Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections. J Clin Microbiol (2011) 1.99
Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev (2013) 1.85
What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection? J Clin Microbiol (2010) 1.70
Evaluation of a loop-mediated isothermal amplification assay for diagnosis of Clostridium difficile infections. J Clin Microbiol (2011) 1.62
Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis (2012) 1.51
Laboratory diagnosis of Clostridium difficile infection can molecular amplification methods move us out of uncertainty? J Mol Diagn (2011) 1.41
Evaluation of the C.Diff Quik Chek Complete Assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of clostridium difficile disease. J Clin Microbiol (2010) 1.38
Comparison of five assays for detection of Clostridium difficile toxin. J Mol Diagn (2011) 1.36
Multicenter clinical evaluation of the portrait toxigenic C. difficile assay for detection of toxigenic Clostridium difficile strains in clinical stool specimens. J Clin Microbiol (2012) 1.34
Loop-mediated isothermal amplification compared to real-time PCR and enzyme immunoassay for toxigenic Clostridium difficile detection. J Clin Microbiol (2011) 1.33
Characterisation and carriage ratio of Clostridium difficile strains isolated from a community-dwelling elderly population in the United Kingdom. PLoS One (2011) 1.29
Is repeat PCR needed for diagnosis of Clostridium difficile infection? J Clin Microbiol (2010) 1.20
Evaluation of three enzyme immunoassays and a loop-mediated isothermal amplification test for the laboratory diagnosis of Clostridium difficile infection. Eur J Clin Microbiol Infect Dis (2012) 1.12
Evaluation of a chromogenic culture medium for isolation of Clostridium difficile within 24 hours. J Clin Microbiol (2010) 1.11
Impact of change to molecular testing for Clostridium difficile infection on healthcare facility-associated incidence rates. Infect Control Hosp Epidemiol (2013) 1.10
Molecular diagnosis of diarrhea: current status and future potential. Curr Infect Dis Rep (2012) 1.07
Perirectal swab surveillance for Clostridium difficile by use of selective broth preamplification and real-time PCR detection of tcdB. J Clin Microbiol (2011) 1.05
Comparison of two commercial molecular assays to a laboratory-developed molecular assay for diagnosis of Clostridium difficile infection. J Clin Microbiol (2010) 1.04
Outcomes in patients tested for Clostridium difficile toxins. Diagn Microbiol Infect Dis (2012) 1.03
Comparison of real-time PCR techniques to cytotoxigenic culture methods for diagnosing Clostridium difficile infection. J Clin Microbiol (2010) 1.03
Clostridium difficile infection. Nat Rev Dis Prim (2016) 0.99
Molecular techniques for diagnosis of Clostridium difficile infection: systematic review and meta-analysis. Mayo Clin Proc (2012) 0.99
Fourteen-genome comparison identifies DNA markers for severe-disease-associated strains of Clostridium difficile. J Clin Microbiol (2011) 0.98
Utilizing rapid multiple-locus variable-number tandem-repeat analysis typing to aid control of hospital-acquired Clostridium difficile Infection: a multicenter study. J Clin Microbiol (2012) 0.96
Rapid diagnosis of Clostridium difficile infection by multiplex real-time PCR. Eur J Clin Microbiol Infect Dis (2011) 0.96
Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model. BMC Infect Dis (2013) 0.96
Evolution of testing algorithms at a university hospital for detection of Clostridium difficile infections. J Clin Microbiol (2012) 0.95
Modifications of commercial toxigenic Clostridium difficile PCR resulting in improved economy and workflow efficiency. J Clin Microbiol (2011) 0.91
Clinical and laboratory evaluation of a real-time PCR for Clostridium difficile toxin A and B genes. Eur J Clin Microbiol Infect Dis (2012) 0.89
Evaluation of a new molecular test, the BD Max Cdiff, for detection of toxigenic Clostridium difficile in fecal samples. J Clin Microbiol (2012) 0.87
Clostridium difficile testing algorithms using glutamate dehydrogenase antigen and C. difficile toxin enzyme immunoassays with C. difficile nucleic acid amplification testing increase diagnostic yield in a tertiary pediatric population. J Clin Microbiol (2012) 0.86
Impact of changes in Clostridium difficile testing practices on stool rejection policies and C. difficile positivity rates across multiple laboratories in the United States. J Clin Microbiol (2013) 0.83
Rational Therapy of Clostridium difficile Infections. Viszeralmedizin (2014) 0.83
Evaluation of the fully automated BD MAX Cdiff and Xpert C. difficile assays for direct detection of Clostridium difficile in stool specimens. J Clin Microbiol (2013) 0.82
Evaluation of a rapid membrane enzyme immunoassay for the simultaneous detection of glutamate dehydrogenase and toxin for the diagnosis of Clostridium difficile infection. Ann Lab Med (2014) 0.82
Community-Acquired Clostridium Difficile Infection: Awareness and Clinical Implications. J Nurse Pract (2013) 0.80
Comparison of a frozen human foreskin fibroblast cell assay to an enzyme immunoassay and toxigenic culture for the detection of toxigenic Clostridium difficile. Diagn Microbiol Infect Dis (2012) 0.80
Evaluation of the Qiagen artus C. difficile QS-RGQ Kit for Detection of Clostridium difficile Toxins A and B in Clinical Stool Specimens. J Clin Microbiol (2015) 0.80
Diagnostic accuracy of loop-mediated isothermal amplification in detection of Clostridium difficile in stool samples: a meta-analysis. Arch Med Sci (2015) 0.79
Laboratory Experience with the Liaison Analyzer in the Diagnosis of Clostridium Difficile-Associated Diarrhea. Eur J Microbiol Immunol (Bp) (2016) 0.78
Evaluation of a new automated homogeneous PCR assay, GenomEra C. difficile, for rapid detection of Toxigenic Clostridium difficile in fecal specimens. J Clin Microbiol (2013) 0.78
Extraction and sensitive detection of toxins A and B from the human pathogen Clostridium difficile in 40 seconds using microwave-accelerated metal-enhanced fluorescence. PLoS One (2014) 0.78
Superiority of the DNA amplification assay for the diagnosis of C. difficile infection: a clinical comparison of fecal tests. Dig Dis Sci (2012) 0.78
Comparison of BD Max Cdiff and GenomEra C. difficile molecular assays for detection of toxigenic Clostridium difficile from stools in conventional sample containers and in FecalSwabs. Eur J Clin Microbiol Infect Dis (2015) 0.77
Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of Clostridium difficile Toxins in Stool. J Clin Microbiol (2015) 0.77
Implementation of Polymerase Chain Reaction to Rule Out Clostridium difficile Infection Is Associated With Reduced Empiric Antibiotic Duration of Therapy. Hosp Pharm (2014) 0.76
Glutamate dehydrogenase for laboratory diagnosis of Clostridium difficile infection. J Clin Microbiol (2010) 0.76
Evaluation of Xpert C. difficile, BD MAX Cdiff, IMDx C. difficile for Abbott m2000, and Illumigene C. difficile Assays for Direct Detection of Toxigenic Clostridium difficile in Stool Specimens. Ann Lab Med (2016) 0.76
Current knowledge on the laboratory diagnosis of Clostridium difficile infection. World J Gastroenterol (2017) 0.75
The Daniel K. Inouye College of Pharmacy Scripts: Updates on Clostridium difficile Infection: Advances in Laboratory Testing to Aid Diagnosis and Treatment. Hawaii J Med Public Health (2017) 0.75
Combination of culture, antigen and toxin detection, and cytotoxin neutralization assay for optimal Clostridium difficile diagnostic testing. Can J Infect Dis Med Microbiol (2013) 0.75
Cost and Impact on Patient Length of Stay of Rapid Molecular Testing for Clostridium difficile. Infect Dis Ther (2014) 0.75
Ultrasensitive Detection and Quantification of Toxins for Optimized Diagnosis of Clostridium difficile Infection. J Clin Microbiol (2015) 0.75
Host response to Clostridium difficile infection: Diagnostics and detection. J Glob Antimicrob Resist (2016) 0.75
A Decade of Development of Chromogenic Culture Media for Clinical Microbiology in an Era of Molecular Diagnostics. Clin Microbiol Rev (2017) 0.75
False Negative Results in Clostridium difficile Testing. BMC Infect Dis (2016) 0.75
Variability in testing policies and impact on reported Clostridium difficile infection rates: results from the pilot Longitudinal European Clostridium difficile Infection Diagnosis surveillance study (LuCID). Eur J Clin Microbiol Infect Dis (2016) 0.75
Can we improve the therapy of Clostridium difficile infection in elderly patients? Wien Klin Wochenschr (2016) 0.75
Novel portable platform for molecular detection of toxigenic Clostridium difficile in faeces: a diagnostic accuracy study. Eur J Clin Microbiol Infect Dis (2016) 0.75
The emergence of Clostridium difficile PCR-ribotype 001 in Slovakia. Eur J Clin Microbiol Infect Dis (2015) 0.75
Comprehensive evaluation of chemiluminescent immunoassays for the laboratory diagnosis of Clostridium difficile infection. Eur J Clin Microbiol Infect Dis (2017) 0.75
An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med (2005) 16.59
Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol (2009) 7.89
Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis (2008) 4.07
Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun (1978) 3.93
Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. Clin Infect Dis (2007) 3.24
Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol (2008) 3.21
Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J Clin Microbiol (2008) 3.15
A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother (2008) 3.01
Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J Clin Microbiol (2007) 2.77
Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol (2001) 2.42
Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J Clin Microbiol (2007) 2.05
Is a two-step glutamate dehyrogenase antigen-cytotoxicity neutralization assay algorithm superior to the premier toxin A and B enzyme immunoassay for laboratory detection of Clostridium difficile? J Clin Microbiol (2008) 1.88
Multicenter evaluation of a new screening test that detects Clostridium difficile in fecal specimens. J Clin Microbiol (2004) 1.71
"Second-look" cytotoxicity: an evaluation of culture plus cytotoxin assay of Clostridium difficile isolates in the laboratory diagnosis of CDAD. J Hosp Infect (2001) 1.49
The effects of storage conditions on viability of Clostridium difficile vegetative cells and spores and toxin activity in human faeces. J Clin Pathol (2003) 1.46
Laboratory diagnosis of clostridium difficile infection. An evaluation of tests for faecal toxin, glutamate dehydrogenase, lactoferrin and toxigenic culture in the diagnostic laboratory. Br J Biomed Sci (2009) 1.30
Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med (2014) 5.05
Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev (2013) 4.63
Multilocus sequence typing of Clostridium difficile. J Clin Microbiol (2009) 4.16
Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet (2012) 4.10
Clinical Clostridium difficile: clonality and pathogenicity locus diversity. PLoS One (2011) 2.04
Microevolutionary analysis of Clostridium difficile genomes to investigate transmission. Genome Biol (2012) 2.04
Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother (2008) 1.98
Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement. Lancet Infect Dis (2008) 1.96
Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis (2010) 1.92
The Early Transmission Dynamics of H1N1pdm Influenza in the United Kingdom. PLoS Curr (2009) 1.87
Improving early management of bloodstream infection: a quality improvement project. BMJ (2008) 1.73
Bayesian modeling to unmask and predict influenza A/H1N1pdm dynamics in London. Proc Natl Acad Sci U S A (2011) 1.58
Barrett's, blood groups and progression to oesophageal cancer: is nitric oxide the link? Eur J Gastroenterol Hepatol (2011) 1.56
Reduced susceptibility to chlorhexidine in staphylococci: is it increasing and does it matter? J Antimicrob Chemother (2012) 1.46
A simple prophylaxis regimen for MRSA: its impact on the incidence of infection in patients undergoing liver resection. Ann R Coll Surg Engl (2009) 1.42
Reference assays for Clostridium difficile infection: one or two gold standards? J Clin Pathol (2010) 1.41
Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med (2015) 1.34
Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acinetobacter baumannii around London. Int J Antimicrob Agents (2009) 1.30
Systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis (2006) 1.11
Adding amikacin to fluoroquinolone-based antimicrobial prophylaxis reduces prostate biopsy infection rates. BJU Int (2010) 1.11
Effectiveness of antibiotics given before admission in reducing mortality from meningococcal disease: systematic review. BMJ (2006) 1.09
Comparison of diagnostic sensitivity and specificity of seven Cryptosporidium assays used in the UK. J Med Microbiol (2011) 1.09
Effectiveness of antibiotics in preventing meningococcal disease after a case: systematic review. BMJ (2004) 1.08
Epidemiology, diagnosis and treatment of Clostridium difficile infection. Expert Rev Anti Infect Ther (2012) 1.03
Automated biosurveillance data from England and Wales, 1991-2011. Emerg Infect Dis (2013) 1.00
Non-culture detection of Streptococcus agalactiae (Lancefield group B Streptococcus) in clinical samples by real-time PCR. J Med Microbiol (2012) 1.00
An improved algorithm for outbreak detection in multiple surveillance systems. Stat Med (2012) 0.98
Helicobacter hypothesis for idiopathic parkinsonism: before and beyond. Helicobacter (2008) 0.94
Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections? J Antimicrob Chemother (2011) 0.93
Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter (2005) 0.90
The changing aetiology of paediatric bacteraemia in England and Wales, 1998-2007. J Med Microbiol (2009) 0.89
Differential effect of Helicobacter pylori eradication on time-trends in brady/hypokinesia and rigidity in idiopathic parkinsonism. Helicobacter (2010) 0.88
Role of inflammation in gastrointestinal tract in aetiology and pathogenesis of idiopathic parkinsonism. FEMS Immunol Med Microbiol (2005) 0.86
Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study. Gut Pathog (2012) 0.84
Sporadic cryptosporidiosis decline after membrane filtration of public water supplies, England, 1996-2002. Emerg Infect Dis (2005) 0.83
An assessment of bacterial dysbiosis in pouchitis using terminal restriction fragment length polymorphisms of 16S ribosomal DNA from pouch effluent microbiota. Dis Colon Rectum (2009) 0.82
Measurement of toxin production by Clostridium difficile. Lancet (2006) 0.81
Early-onset neonatal group B streptococcal infection in London: 1990-1999. BJOG (2004) 0.81
Limited impact on endoscopy demand from a primary care based 'test and treat' dyspepsia management strategy: the results of a randomised controlled trial. Br J Gen Pract (2006) 0.80
Towards defining a rigidity-associated pathogenic pathway in idiopathic parkinsonism. Neurodegener Dis (2011) 0.78
New and emerging therapies for Clostridium difficile infection. Curr Opin Infect Dis (2016) 0.78
Serogroup-specific Seasonality of Verotoxigenic Escherichia coli, Ireland. Emerg Infect Dis (2016) 0.76
Assuring the quality of diagnostic tests: how do we know that they do what we think they do? BMJ (2013) 0.75
Prevalence of and risks for internal contamination among hospital staff caring for a patient contaminated with a fatal dose of polonium-210. Infect Control Hosp Epidemiol (2011) 0.75
Malignant clear cell hidradenoma of the vulva: report of a unique case and review of the literature. Int J Gynecol Pathol (2008) 0.75